Skip to content
Head to head

Arrowhead Pharmaceuticals vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: ARWR · VRTX

Updated 8 minutes ago

1-year performance, rebased to 100

ARWR +3.0%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals has the highest Quant Rating (68); Vertex Pharmaceuticals has done best over the past year (+22%); Vertex Pharmaceuticals earns the most per share.
ARWRVRTX
Snapshot
Sector--Biotechnology
Last price41.37515.02
Change today-5.22%-1.08%
1-year return+8.6%+22.0%
Market cap$5.85B$130.58B
52-week range40.43 – 95.49412.27 – 568.67
Valuation
P/E (TTM)-8.1033.14
P/E percentile, own 5-yr range73rd99th
P/B116.216.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-5.1115.32
Net profit (TTM)$-722.39M$3.88B
Revenue (TTM)$450.82M$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)-85.3%+11.8%
Gross margin99.6%85.5%
Operating margin-156.9%33.1%
Net margin-160.6%30.7%
Free cash flow (TTM)$-283.94M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership90.9%96.8%
Insider activity (12mo)12 buy / 37 sell28 buy / 22 sell
Short interest (% of float)8.2%1.9%
Analyst consensus91% buy / 9% hold (11)95% buy / 5% hold (21)
Analyst price target$107 (+158%)$624 (+21%)
StockVane view
StockVane Quant RatingD (48)C (68)
Company
Employees7116,400
Founded19891989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.